Clinical Trial Update: ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefitinib (ZD-1839) in metastatic or recurrent head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED